Furthermore, our evidence of an oncogenic GOF leading to aggressive metastatic tumors in Trp53YC/YC male mice is consistent with the oncogenic GOF attributed to p53Y220C in male patients with glioblastoma (Rockwell et al., 2021) or with experiments suggesting that p53Y220C expression in p53-null cells, or its overexpression in MCF-10A cells, may increase their migratory or invasive capacities (Pal et al., 2023; Zhou et al., 2022). The gene discussed is TP53; the disease is glioblastoma.